Pharmafile Logo

Top-10 ways that Pharma teams can fight the climate crisis

Ten easy steps that individual medical, marketing, clinical, regulatory, and market access teams can take to reduce their own footprints.

I recently attended a webinar called “Pharma’s climate goals: The roadmap to delivery.” It was an eye-opening discussion focused on the big changes that pharmaceutical organizations need to implement to reduce their carbon footprint. In this top-10 article, I wanted to build on the insights shared during that webinar, with a focus on the smaller–but just as important–steps that individual medical, marketing, clinical, regulatory, and market access teams can take to reduce their own footprints, contributing to their organizations’ bottom lines. These include:

1. Set clear short-, mid-, and long-term goals
2. Reduce your energy use or switch to sustainable sources of energy
3. Continue to let your team work remotely or flexibly
4. Consider decentralized trials
5. Take a critical look at your supply chain

Read the full top-10 list of ways that Pharma teams can reduce their environmental footprint and fight the climate crisis here.

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Patient Advocate Engagement: A Customer Story

Learn how our client executed a series of 3 virtual touchpoints with 5 rare disease patient advocates to:- Develop a better understanding of the current treatment landscape and lived patient...

Tailored Marketing Strategies for Pharma – Top 10 Most Important Advisor Questions

In this video, we explore another crucial aspect of advisor questions when developing your virtual advisory board touchpoints – a key component for success in today's diverse healthcare landscape. 7....

Trends in Virtual Collaboration

Join us for a look at the top-5 emerging virtual collaboration trends...

Advisor Questions on Potential Data or Knowledge Gaps

As part of our top 10 most important advisor questions that every brand team should keep in mind when designing virtual advisory board touchpoints, here's another one to keep in...

On a journey to diverse, inclusive, and more efficient rare disease trials

Although orphan drugs represent a sizeable portion of new drug approvals, most rare diseases still lack effective treatment. Even more so than for other conditions, rare disease management contains large care...

Versatility! Top 10 benefits of virtual advisory boards

Here's another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #10. Versatility! Another major advantage of using a virtual platform...

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story

In the early lead-up to our client’s multi-center Rare Disease Phase 3 Clinical Trial, they first conducted an internal engagement planning Longitudinal Expert Engagement Plan™ (LEEP™) to conduct an informal...

New Playbook Alert: Virtual Patient Engagement

Authentic patient engagement and insight-gathering are becoming must-haves in Pharma. However, multiple obstacles remain before patient-centricity becomes more than a buzzword. In our latest playbook, we take a deep dive...

No “White Space” Between Live Meetings; the top 10 benefits of virtual advisory boards

Here's another great tip on why the benefits of virtual advisory boards are superior to in-person and hybrid advisory boards. #9. No More “White Space” Between Live Meetings Clearly, the...

The problem with clinical trials (and how virtual insight-gathering can help)

While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access.